Delivery Order SPE2DB22D2206-SPE2DB25FHQ33
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,131.74 to AmerisourceBergen Drug Corp for the supply of Prograf 1 mg capsules (100-count units). This firm fixed-price delivery order, issued on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $36,127.45 to AmerisourceBergen Drug Corp for the supply of Prograf 1 mg capsules (100-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, firm fixed-price contract was competitively awarded and represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $41,735.37 to AmerisourceBergen Drug Corp for the supply of Prograf 5 mg capsules (100 count units) under a firm fixed price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This non-set-aside award represents a competitively awarded transaction for a critical pharmaceutical...
- The Defense Logistics Agency awarded a $18,879.92 delivery order to AmerisourceBergen Drug Corp for Prograf 1 mg capsules (100-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed at the contractor's facility in Conshohocken, Pennsylvania. Prograf (tacrolimus) is an immunosuppressant medication commonly used in transplant medicine and autoimmune disease management, representing part...
- The Defense Logistics Agency awarded a $1,926.55 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Tacrolimus 1 mg capsules (100-count units). This firm fixed price contract, which is not set-aside, represents a single delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $8,158.47 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 4561757478 ! PROGRAF 1 MG CAPSULE 100S. As the prime contractor, Amerisourcebergen Drug Corporation will deliver the requested pharmaceutical product to the location of performance in Conshohocken, Pennsylvania within the period of performance between August 9-10, 2023. The Defense Logistics Agency is the funding agency for this delivery order placed against an existing...
- This federal contract award, valued at $1,230.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of Prograf 1 mg capsules, a medication used for transplant patients. The contract has an ultimate completion date of September 24, 2024 and is a firm fixed-price agreement. It is not designated as a set-aside contract, indicating open...
- This is a $1,303.59 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of PROGRAF 1 MG CAPSULE 100S, with a period of performance through May 30, 2025. The contract is not set aside and was awarded on an open competition basis. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Conshohocken, Pennsylvania. The $7,004.70 firm fixed price delivery order is for the supply of PROGRAF 1 MG CAPSULE 100S, a medication likely used in the treatment of medical conditions. The contract has an ultimate completion date of July 7, 2025. Amerisourcebergen Drug Corp holds a larger...
- The Defense Logistics Agency awarded a $4,429.75 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 4561683195 Prograf 1 mg capsules in quantities of 100. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is August 2 to August 3, 2023. The Defense Logistics Agency manages the global supply chain for the United States Department of Defense and supports its various procurement...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHQ33Delivery Order
The Defense Logistics Agency awarded a $1,738.12 delivery order to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of Prograf 1 mg capsules (100-count units). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with a completion date of June 26, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. As the prime contractor on this delivery order, the company leverages its comprehensive pharmaceutical supply portfolio through the DLA's global pharmaceutical support vehicle to deliver specialized medications across multiple therapeutic domains. This transaction exemplifies the company's role in fulfilling federal medical supply needs through open competition and demonstrates its capability to meet urgent delivery requirements within the Defense Logistics Agency's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 6/25/25 |